Promis Neurosciences Inc. · NASDAQ:PMN
Promis Neurosciences — Technical Presentation (July 2026)
27 slides from Promis Neurosciences's technical presentation, Jul 22, 2026
Slide 1: Safety & Biomarker Assessment Update
PRECISE-AD PMN310 · PHASE 1b BLINDED 6-MONTH INTERIM ANALYSIS Safety & Biomarker Assessment Update Blinded Interim Analysis Topline results expected Q1 2027 1
Slide 2: Forward-Looking Statements & Disclaimers
LEGAL DISCLOSURES Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such information involves known an
Slide 3: Table of Contents
Table of Contents Slides 4-5: Company Overview, KOL Bios Slides 6-11: PRECISE-AD Phase 1b Trial Design and Patient Demographics Slides 12-16: Blinded Safety Assessment Slides 17-23: Blinded Biomarker Assessment Slides 24-27: Summary and Conclusions 3
Slide 4: Presenters & KOL Participants
Presenters & KOL Participants PRESENTERS Neil Warma President & CEO ProMIS Neurosciences KEY OPINION LEADER KEY OPINION LEADER Dr. Will Mantyh Dr. Michael Weiner Dr. Larry Altstiel Behavioral Neurologist Professor Emeritus, UCSF Chief Medical Officer University of Minnesota Principal Investigator, A
Slide 5: Company Snapshot
COMPANY SNAPSHOT Clinical-stage biotechnology TOP-LINE DATA Early Q1 2027 company with a pipeline designed PRECISE-AD Phase 1b readout to selectively target specific, PEAK SALES >$10B disease-causing misfolded proteins POTENTIAL PMN310 in early Alzheimer's FINANCIAL Up to $175M raised Unique selecti
Slide 6: Execution on Track, Progressing Quickly Toward Topline Results
TRIAL MILESTONES Execution on Track, Progressing Quickly Toward Topline Results DEC 2025 JUN 2026 EARLY Q3 2026 DEC 2026 EARLY Q1 2027 Enrollment 6-Month Dosing Interim Data 12-Month Dosing Topline Results n = 144 complete complete this presentation expected to complete for all patients final readou
Slide 7: PRECISE-AD Study Design & Patient Demographics
PRECISE-AD Study Design & Patient Demographics 7
Slide 8: PRECISE-AD: Phase 1b Trial Design
TRIAL DEMOGRAPHICS AND DESIGN PRECISE-AD: Phase 1b Trial Design KEY STUDY PARAMETERS & PATIENT DEMOGRAPHICS RANDOMIZATION · 3:1 DRUG TO PLACEBO Study PRECISE-AD · Phase 1b Drug ~75% 136 patients Safety-Evaluable Drug (~75%) Placebo (~25%) Agent PMN310 - humanized IgG1 mAb Patient population Mild Cog
Slide 9: Subjects Evaluated to Confirm MCI due to AD or Early AD
TRIAL EXECUTION & DEMOGRAPHICS Subjects Evaluated to Confirm Mild Cognitive Impairment (MCI) due to AD or Early AD CONFIRMATION CRITERIA Clinical Criteria NIA-AA criteria: MCI due to AD or mild AD dementia 100% Amyloid-Positive Confirmed on PET imaging Cognitive Staging MMSE* 20–30 & CDR Global 0.5–
Slide 10: PRECISE-AD: Enrollment Consistent with Real World AD Population
TRIAL DEMOGRAPHICS PRECISE-AD: Enrollment Consistent with Real World AD Population PRECISE-AD PATIENT POPULATION WHY THIS MATTERS ✓ Representative population, including highest ARIA-risk patients 11% APOE4/4 Homozygous Highest ARIA-risk subgroup with plaque-binding therapies ✓ Treatment options may
Slide 11: Many Patients are Currently Well Beyond 6 Months of Treatment
SAFETY Many Patients are Currently Well Beyond 6 Months of Treatment TREATMENT EXPOSURE TO DATE 0 (initiation) 6 mo 9 mo 12 mo n=136 (100%) of patients are past 6 months of dosing n=107 (78%) of patients are past 9 months of dosing n=67 (49%) of patients have completed the full 12-month trial • All
Slide 12: Blinded Safety Assessment
Blinded Safety Assessment 12
Slide 13: Favorable Safety Data, Observed Across Key Measures
INTERIM SAFETY · 6-MONTH BLINDED Favorable Safety Data, Observed Across Key Measures 6-month blinded interim · N = 144 dosed, 136 safety-evaluable · a representative population 0.0% ARIA-E No treatment-related No treatment-related 4.4% total ARIA serious AEs discontinuations The most severe treatmen
Slide 14: Cumulative ARIA-E Over Time: Zero Edema Observed First 6 Months
TIME-MATCHED SAFETY Cumulative ARIA-E Over Time: Zero Edema Observed First 6 Months ARIA-E (the most serious ARIA type) has been observed to occur almost entirely in the first six months of dosing. Comparator ARIA-E plateaus after the first few months; rates are time-matched to published data where
Slide 15: Cumulative Total ARIA Over Time: Tracks Placebo Range
TIME-MATCHED SAFETY Cumulative Total ARIA Over Time: Blinded PRECISE-AD Data Tracks the Placebo Range Reported in Other Trials Approved anti-amyloids accrue ARIA steeply in the first months of dosing, with 90%+ ARIA-E occurring in the first 6 months. Comparator rates are time-matched to published da
Slide 16: APOE4: Higher-risk Patient Population for ARIA-E
A P O E 4 G E N O T Y P E · C L A S S D I F F E R E N T I AT I O N APOE4: Higher-risk Patient Population for ARIA-E ARIA risk rises sharply with APOE4 carrier status. Approved drugs carry boxed warnings and the worst risk/benefit profile, especially for homozygotes, who represent ~15% of patients. A
Slide 17: Blinded Biomarker Assessment
Blinded Biomarker Assessment 12
Slide 18: Two complementary biomarkers: plasma pTau217 and CSF MTBR-tau243
6-MONTH BLINDED INTERIM ANALYSIS Two complementary biomarkers: plasma pTau217 and CSF MTBR-tau243 Presenting 6-month blinded interim data on two biomarkers chosen to bracket the disease cascade. UPSTREAM · PLASMA · AMYLOID-DRIVEN DOWNSTREAM · CSF · TANGLE-SPECIFIC Plasma pTau217 CSF MTBR-tau243 The
Slide 19: pTau217: early blood-based readout of AD biology
BIOMARKER RATIONALE pTau217: early blood-based readout of AD biology 6-month pTau217 is a sensitive early signal, not a standalone efficacy claim. Potential to inform dose selection and bridge to later clinical outcomes. What it measures Representative Natural History Disease progression: a downstre
Slide 20: PRECISE-AD RESULTS: Plasma pTau217 declined steadily through Day 169
6-MONTH BLINDED ANALYSIS · PLASMA PRECISE-AD RESULTS: Plasma pTau217 declined steadily through Day 169 PRECISE-AD Mean % change from baseline over time PRECISE-AD patients with a day-169 decline 5 80 68.5% 0 60 Randomization 3:1 % change from baseline -5 -10 Aggregated drug + placebo (3:1) 40 31.5%
Slide 21: CSF MTBR-tau243: tangle-specific marker of AD pathology
BIOMARKER RATIONALE CSF MTBR-tau243: tangle-specific marker of AD pathology What it measures A CSF marker of tauopathy, the pathology most closely tied to Natural history progression symptoms. What the published evidence supports Time matched longitudinal data for CSF MTBR-tau243 is limited but has
Slide 22: PRECISE-AD RESULTS: CSF MTBR-tau243 declined steadily through Day 169
6-MONTH BLINDED ANALYSIS · CSF PRECISE-AD RESULTS: CSF MTBR-tau243 declined steadily through Day 169 PRECISE-AD Mean % change, screen → Day 169 PRECISE-AD: Patients with a Day-169 decline 5 80 0 62.5% 60 Randomization 3:1 % change from baseline -5 -10 Aggregated drug + placebo (3:1) 40 37.5% -15 -13
Slide 23: Two biomarkers, one coherent 6-month signal
BIOMARKER SUMMARY Two biomarkers, one coherent 6-month signal UPSTREAM · PLASMA DOWNSTREAM · CSF pT217 declined through Day 169 MTBR-tau243 declined through Day 169 A steady overall decline of 15% vs baseline with This tangle-specific marker declined by 13.3% in the ~68% of all patients showing a re
Slide 24: Summary & Conclusions
ProMIS™ Neurosciences Summary & Conclusions
Slide 25: A Differentiated, Precision Approach to Alzheimer's — With a Clear Path Forward
CONCLUSION A Differentiated, Precision Approach to Alzheimer’s — With a Clear Path Forward PRECISE-AD’s blinded interim analysis shows favorable safety data and early, mechanism-consistent biomarker signals, supporting a differentiated approach for patients underserved by approved anti-amyloid thera
Slide 26: Topline results early Q1 2027
Topline results early Q1 2027 Favorable safety profile Early biomarker signals Oligomer-selective MOA No ARIA-E, zero SAEs — across all Directional trends consistent with Designed to decouple efficacy from ARIA genotypes. potential target engagement. liability with precision selectivity. PMN : NASDA
Slide 27: For further information, contact: info@promisneurosciences.com
For further information, contact: info@promisneurosciences.com NASDAQ: PMN 26
ProMIS Neurosciences — Technical Presentation (July 2026) on 6ix